Highest-materiality recent filing
Rein Therapeutics receives Nasdaq delisting notice for bid price below $1.00
Received delisting notice from Nasdaq on Aug 21, 2026 for bid price below $1.00 for 30 consecutive trading days.
Rein Therapeutics prices $50M public offering of 50M shares at $1.00/share
Gross proceeds $50M from 50M shares at $1.00; net proceeds ~$46.1M after discounts and expenses.
Rein Therapeutics issues $2.875M in unsecured notes to institutional investors at 20% OID
Issued $2.875M aggregate principal notes for $2.3M net cash (20% original issue discount).
FDA lifts clinical hold on Rein Therapeutics' Phase 2 trial of LTI-03 for IPF
FDA lifted full clinical hold after Rein's Complete Response submission; agency confirmed all concerns resolved.
Rein Therapeutics receives EMA authorization to begin Phase 2 trial of LTI-03 for IPF
European Medicines Agency approved Phase 2 RENEW trial at clinical sites in Germany and Poland.
FDA confirmed MCH/H findings in GLP rat studies are not dose-limiting for proposed 24-week LTI-03 protocol at doses up to 10 mg/day in IPF patients.
Rein Therapeutics secures up to $6.0M in prepaid advances from Yorkville; second $1.0M tranche drawn
Entered Pre-Paid Advance Agreement with Yorkville for up to $6.0M over 12 months; initial $1.0M advance closed July 29, 2025.
Rein Therapeutics gets UK MHRA nod for Phase 2 IPF trial of LTI-03
UK MHRA authorized Phase 2 'RENEW' trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
Rein Therapeutics enters up to $21M financing with Yorkville via PPA and SEPA
Pre-Paid Advance Agreement: up to $6M; initial $1M advance at 95% net ($0.95M); 8% annual interest rising to 18% on default.
FDA placed Phase 2 RENEW trial of LTI-03 on clinical hold on July 8, 2025 via formal letter.
Rein Therapeutics pauses US enrollment in Phase 2 RENEW trial due to FDA clinical hold
FDA placed clinical hold on Phase 2 RENEW trial of LTI-03 on June 10, 2025; US enrollment and dosing paused.
Rein Therapeutics Q1 net loss $5.5M; Phase 2 IPF trial initiated
Net loss $5.5M ($0.25/shr) vs $7.1M ($0.86/shr) year ago; revenue not reported.
Rein Therapeutics raises ~$5.05M via warrant exercises, exchanges, and private placement
Holders exercise 2023 and 2024 warrants for 902,929 shares at reduced price of $1.60 per share.
Rein Therapeutics auditor Marcum resigns, CBIZ appointed; going concern noted
Marcum LLP resigned as independent auditor on April 16, 2025; CBIZ CPAs P.C. engaged by Audit Committee.
Aileron Therapeutics reports Q3 net loss of $5.8M; Phase 1b LTI-03 shows positive biomarker data
Net loss of $5.8M ($0.27 per share) compared to $1.8M ($0.40) in Q3 2023; R&D expenses increased to $3.7M from $0.1M.
Aileron Q2 2024 net loss $8.9M; positive Phase 1b data for LTI-03 in IPF
Net loss of $8.9M ($0.45 per share) vs $1.8M in Q2 2023; R&D expenses surged to $3.7M from $0.2M.
Aileron Therapeutics appoints Timothy Cunningham as interim CFO after Charles Garner departure
Charles Garner departed as CFO on May 15, 2024; Timothy Cunningham appointed interim CFO effective May 16, 2024.
Aileron posts Q1 net loss of $7.1M; positive Phase 1b data for LTI-03 in IPF
Q1 net loss $7.1M ($0.86/share) vs $4.8M ($1.05) in Q1 2023; R&D expenses rose to $3.5M from $1.8M.
Aileron reports positive LTI-03 Phase 1b Cohort 1 IPF data; cash $12.0M
7 of 8 biomarkers showed positive trend; 3 statistically significant: GAL-7 (p=0.0014), TSLP (p=0.0223), Col-1α1 (p=0.0489).
Aileron Therapeutics prices ~$20M registered direct offering of stock and warrants
4,273,505 shares and accompanying warrants sold at combined $4.68/unit; gross proceeds ~$20M, net ~$17.9M.
Interim CFO Drexler resigns; Garner appointed PFO/PAO, will depart May 15, 2024
Susan L. Drexler resigned as Interim CFO, PFO and PAO effective March 25, 2024; remains consultant via Danforth Advisors.
Aileron CEO Manuel Aivado resigns; President Brian Windsor named CEO effective March 11, 2024
Manuel Aivado steps down as CEO effective March 11, 2024, remains on the Board.
Lung Therapeutics net loss $19.0M in 2022, $9.9M in 2021; cash and equivalents $11.9M at Dec 31, 2022.
Aileron receives Nasdaq deficiency notice for missing annual meeting; appoints Marcum as auditor
Received Nasdaq notice on Jan 4, 2024 for failing to hold annual meeting within 12 months after FY2022 end.
Aileron acquires Lung Therapeutics in stock deal, raises $18M via PIPE, appoints new COO
Acquired Lung Therapeutics for 344,566 shares of common stock and 20,140 shares of Series X Preferred; post-merger shares outstanding ~4.89M.
Aileron terminates ALRN-6924 Phase 1b trial; cuts workforce to 3; explores strategic alternatives
Phase 1b trial showed Grade 4 neutropenia and alopecia; primary endpoint not met; development of ALRN-6924 terminated.
Aileron stops NSCLC trial enrollment after interim data; revises breast cancer trial
Interim data from 20 patients: ALRN-6924 patients completed 93% of first 4 chemo cycles vs 78% placebo.
Aileron appoints interim CFO; shareholders approve reverse stock split (1:5–1:25)
Susan L. Drexler appointed interim CFO effective June 16, 2022, via consulting agreement with Danforth Advisors.
Aileron Therapeutics fails to regain Nasdaq bid price compliance; granted extension to Dec 5, 2022
Received deficiency notice Dec 2021 for bid price below $1.00; initial 180-day period ended June 6, 2022 without compliance.
CFO Richard J. Wanstall resigns effective May 6, 2022 for other opportunity
Richard J. Wanstall, CFO and principal accounting officer, resigns effective May 6, 2022 to pursue another career opportunity.
the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.
Mr. Garner's departure from the Company on May 15, 2024.
the Board of Directors of the Company appointed Charles Garner to serve as the Company’s principal financial officer and principal accounting officer, effective as of March 25, 2024.
On March 25, 2024, Susan L. Drexler, Interim Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc. (the “Company”), notified the Company of her resignation, effective as of March 25, 2024.
Separately, the Company and Mr. Garner have agreed that his employment with the Company will end effective as of May 15, 2024.
the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024
Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024
the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024
On February 29, 2024, Nolan Sigal, M.D., Ph.D., notified Aileron Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective immediately.
On October 30, 2023, the Board approved the appointment of Brian Windsor, Ph.D., age 57, to President and Chief Operating Officer of Aileron, effective as of the consummation of the Merger.
Following Mr. Bailey's resignation, Josef H. von Rickenbach will serve as the Chairman of the Board.
On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.
Max materiality 0.90 · Median 0.60 · Most common event other_material